METHODS AND COMPOSITIONS FOR TREATING CONDITIONS
    62.
    发明申请
    METHODS AND COMPOSITIONS FOR TREATING CONDITIONS 审中-公开
    处理条件的方法和组成

    公开(公告)号:US20090069237A1

    公开(公告)日:2009-03-12

    申请号:US12176235

    申请日:2008-07-18

    申请人: Hanna Skubatch

    发明人: Hanna Skubatch

    IPC分类号: A61K38/16 C07K14/00 A61P25/00

    摘要: The invention relates to compositions that can be used to treat, prevent, and modulate pain, inflammation, and metabolic processes in various organisms including plants and animals. Such compositions can be formulated with an acceptable pharmaceutical excipient for administration to a human or a plant. The compositions can be administered topically or for systemic use.

    摘要翻译: 本发明涉及可用于治疗,预防和调节包括植物和动物在内的各种生物体内的疼痛,炎症和代谢过程的组合物。 这样的组合物可以用可接受的药物赋形剂配制,用于给人或植物施用。 组合物可以局部施用或用于全身使用。

    Method for alleviating pain or providing an analgesic effect in a patient
    65.
    发明授权
    Method for alleviating pain or providing an analgesic effect in a patient 失效
    减轻疼痛或在患者中提供镇痛作用的方法

    公开(公告)号:US06610825B2

    公开(公告)日:2003-08-26

    申请号:US09798119

    申请日:2001-03-01

    IPC分类号: C07K700

    摘要: Conjugates are prepared from antinociceptive agents, particularly opioids or opioid analogs, more particularly dynorphins, endorphins, deltorphins, enkephalins or analogs thereof, by combining said antinociceptive agent with a material providing a functionally reactive group capable of reacting with a blood component (preferably a blood cell or protein). Said conjugates permit extension of the therapeutic life of the antinociceptive agent. They may be administered to patients to alleviate pain, produce analgesic effects, or assist in cases of narcotics withdrawal, and may also be used as probes for receptor activity. The administration to the patient may be made either in vivo or ex vivo and may be performed by either introducing the derivative including the reactive functional group into the patient's vascular system or preparing such a conjugate externally (or in vitro) and introducing that conjugate to the patient's vascular system.

    摘要翻译: 通过将所述抗伤害感受剂与提供能够与血液成分(优选血液)反应的功能反应性基团的材料组合,由抗伤害感受剂,特别是阿片样物质或阿片样物质类似物,更具体地说是强啡肽,内啡肽,delphphins,脑啡肽或其类似物制备缀合物 细胞或蛋白质)。 所述缀合物允许延长抗伤害感受剂的治疗寿命。 可以向患者施用以缓解疼痛,产生镇痛作用或辅助麻醉药物撤出的情况,也可用作受体活性的探针。 对患者的施用可以在体内或体外制备,并且可以通过将包含反应性官能团的衍生物引入患者的血管系统或者在外部(或体外)中制备这种缀合物并将该缀合物引入到 患者血管系统。

    Antinociceptive agent derivative
    66.
    发明授权

    公开(公告)号:US06602981B2

    公开(公告)日:2003-08-05

    申请号:US09798114

    申请日:2001-03-01

    IPC分类号: C07K700

    摘要: Conjugates are prepared from antinociceptive agents, particularly opioids or opioid analogs, more particularly dynorphins, endorphins, deltorphins, enkephalins or analogs thereof, by combining said antinociceptive agent with a material providing a functionally reactive group capable of reacting with a blood component (preferably a blood cell or protein). Said conjugates permit extension of the therapeutic life of the antinociceptive agent. They may be administered to patients to alleviate pain, produce analgesic effects, or assist in cases of narcotics withdrawal, and may also be used as probes for receptor activity. The administration to the patient may be made either in vivo or ex vivo and may be performed by either introducing the derivative including the reactive functional group into the patient's vascular system or preparing such a conjugate externally (or in vitro) and introducing that conjugate to the patient's vascular system

    Conjugate comprising an antinociceptive agent covalently bonded to a blood component
    67.
    发明授权
    Conjugate comprising an antinociceptive agent covalently bonded to a blood component 失效
    共轭物包含与血液成分共价结合的抗伤害感受剂

    公开(公告)号:US06500918B2

    公开(公告)日:2002-12-31

    申请号:US09798121

    申请日:2001-03-01

    IPC分类号: C07K700

    摘要: Conjugates are prepared from antinociceptive agents, particularly opioids or opioid analogs, more particularly dynorphins, endorphins, deltorphins, enkephalins or analogs thereof, by combining said antinociceptive agent with a material providing a functionally reactive group capable of reacting with a blood component (preferably a blood cell or protein). Said conjugates permit extension of the therapeutic life of the antinociceptive agent. They may be administered to patients to alleviate pain, produce analgesic effects, or assist in cases of narcotics withdrawal, and may also be used as probes for receptor activity. The administration to the patient may be made either in vivo or ex vivo and may be performed by either introducing the derivative including the reactive functional group into the patient's vascular system or preparing such a conjugate externally (or in vitro) and introducing that conjugate to the patient's vascular system.

    摘要翻译: 通过将所述抗伤害感受剂与提供能够与血液成分(优选血液)反应的功能反应性基团的材料组合,由抗伤害感受剂,特别是阿片样物质或阿片样物质类似物,更具体地说是强啡肽,内啡肽,delphphins,脑啡肽或其类似物制备缀合物 细胞或蛋白质)。 所述缀合物允许延长抗伤害感受剂的治疗寿命。 可以向患者施用以缓解疼痛,产生镇痛作用或辅助麻醉药物撤出的情况,也可用作受体活性的探针。 对患者的施用可以在体内或体外制备,并且可以通过将包含反应性官能团的衍生物引入患者的血管系统或者在外部(或体外)中制备这种缀合物并将该缀合物引入到 患者血管系统。